Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have recently shown efficacy in episodic and chronic migraine and will be available soon.

Additional Metadata
Persistent URL dx.doi.org/10.1186/s13073-018-0524-7, hdl.handle.net/1765/104914
Journal Genome Medicine
Citation
Maassen Van Den Brink, A. (Antoinette), Terwindt, G.M, & Maagdenberg, A.M.J.M. (2018). Calcitonin gene-related peptide (receptor) antibodies: An exciting avenue for migraine treatment. Genome Medicine (Vol. 10). doi:10.1186/s13073-018-0524-7